首页> 外文会议>International Symposium on Atherosclerosis >New frontiers in atherosclerosis prevention and treatment: HDL as a novel therapeutic target
【24h】

New frontiers in atherosclerosis prevention and treatment: HDL as a novel therapeutic target

机译:动脉粥样硬化预防和治疗中的新前沿:HDL作为新的治疗目标

获取原文

摘要

The high-density lipoprotein (HDL) system offers an attractive target for novel therapeutic approaches to prevent or treat atherosclerosis Clinical preventative studies with HDL modulators, both increasing HDL levels [peroxisome proliferator activator receptor (PPAR) a agonists] and stimulating turnover [cholesteryl ester transfer protein (CETP) activators] have led to favorable outcomes. Ireatment of preexisting atherosclerosis with novel HDL mimetics, i.e., wild-type recombinant apo A-I, reconstituted HDL from human serum, large unilamellar phospholipid vesicles (LUV), and the recombinant apo A-I_(Milano) dimer (AIM) offer exciting opportunities Recent findings with AIM are consistent with the hypothesis that direct HDL administration can rapidly regress coronary plaques.
机译:高密度脂蛋白(HDL)系统提供了一种有吸引力的新治疗方法,用于预防或治疗HDL调节剂的动脉粥样硬化临床预防性研究,增加HDL水平[过氧化物体增殖物活化剂受体(PPAR)A激动剂]和刺激周转[胆甾醇酯转移蛋白(CETP)活化剂导致有利的结果。用新型HDL模拟物预先存在的动脉粥样硬化,即野生型重组APO AI,来自人血清的重构HDL,大不数型磷脂囊泡(LUV)和重组APO A-I_(Milano)二聚体(AIM)提供令人兴奋的机会目的的发现与直接HDL施用可以快速退化冠状动脉斑块的假设一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号